title: IFITM1 targets HIV-1 latently infected cells for antibody-dependent cytolysis.
abstract: HIV-1 persistence in latent reservoirs during antiretroviral therapy (ART) is the main obstacle to virus eradication. To date, there is no marker that adequately identifies latently infected CD4+T cells in vivo. Using a well-established ex vivo model, we generated latently infected CD4+T cells and identified interferon-induced transmembrane protein 1 (IFITM1), a transmembrane antiviral factor, as being overexpressed in latently infected cells. By targeting IFITM1, we showed the efficient and specific killing of a latently infected cell line and CD4+T cells from ART-suppressed patients through antibody-dependent cytolysis. We hypothesize that IFITM1 could mark natural reservoirs, identifying an immune target for killing of latently infected cells. These novel insights could be explored to develop clinical therapeutic approaches to effectively eradicate HIV-1.
authors.forename: Rui André Saraiva
authors.initials: RAS
authors.lastname: Raposo
authors.forename: Miguel
authors.initials: M
authors.lastname: de Mulder Rougvie
authors.forename: Dominic
authors.initials: D
authors.lastname: Paquin-Proulx
authors.forename: Phillip M
authors.initials: PM
authors.lastname: Brailey
authors.forename: Vinicius D
authors.initials: VD
authors.lastname: Cabido
authors.forename: Paul M
authors.initials: PM
authors.lastname: Zdinak
authors.forename: Allison S
authors.initials: AS
authors.lastname: Thomas
authors.forename: Szu-Han
authors.initials: SH
authors.lastname: Huang
authors.forename: Greta A
authors.initials: GA
authors.lastname: Beckerle
authors.forename: Richard B
authors.initials: RB
authors.lastname: Jones
authors.forename: Douglas F
authors.initials: DF
authors.lastname: Nixon
mesh_terms: D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology*; D000943:Antigens, Differentiation / Q000378:metabolism*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects / Q000276:immunology; D006801:Humans
chemical_list: D044966:Anti-Retroviral Agents; D000943:Antigens, Differentiation; C062010:leu-13 antigen